ACST stock: buy or sell?

ACST stock price: $0.65 3.17% At close on May 22nd, 2020

Updated on:
May 22nd, 2020


Acasti Pharma jumped a wonderful 3.17% and closed at $0.65.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases.

Should I buy ACST stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Following a trading plan helps to make decisions easier, quicker and with less hesitations. At, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Acasti Pharma stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Acasti Pharma stock a buy?

Banks and financial institutions publish stock ratings everyday. Unfortunately, we couldn't find any rating for ACST stock for the last month.

ACST stock analysis

Daily outlook

Shares of Acasti Pharma ended on May/22 at $0.65 and jumped a wonderful 3.17%.

Acasti Pharma closed on May/22 at $0.65 and jumped a wonderful 3.17%. From a daily perspective, ACST is in a short term uptrend after plotting its last bottom ($0.56, on May/4) higher than the previous bottom, and its last top ($0.70, on May 11th) also over the previous top. Now trading in between its last bottom and last top ACST might consolidate in a plain range, waiting to break out over $0.70 or down under $0.56. Since last January when ACST stock price broke down the SMA200d line, it slid $-1.53 per share (-70.18%).

ACST stock chart (daily)

Weekly outlook

Acasti Pharma shares jumped 3.17% this week, ending at $0.65. Late April ACST plummed a spooky -20.37% in just one week. Early May ACST climbed a super good 10.61% in just one week.

Since price and 40-weeks moving average lines crossed down by mid January, ACST fell $-1.53 per share (-70.18%). Stocks below the 200 days moving average line are usually not recommended for average traders.

ACST stock chart (weekly)

ACST stock price history

ACST IPO was on June 6th, 2012 at $20.00 per share1. Since then, ACST stock sliced a -96.80%, with a yearly average of -13.80%.

1: Adjusted price after possible price splits or reverse-splits.

ACST stock historical price chart

ACST stock reached 52-week highs on December at $3.08, and all-time highs 2013-07-24 with a price of 42.

ACST stock price target

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' ACST stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not found any price forecast for Acasti Pharma stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

, Acasti Pharma didn't meet the forecasts of the experts and reported a dreadful EPS of $-0.05 per share when experts were expecting $-0.08.
ACST earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2015, Acasti Pharma annual revenues plunged a frightening -45.97% to $0.27 million USD from $0.50 marked in 2014. When comparing 2015 vs 2014, nevertheless, profit margin (that is, the net income divided by revenues) boosted a 1,706.37% to -611.57%.

ACST annual Sales and Income evolution
2013$0.72 M-$-6.89 M-951.4%-
2014$0.50 M-30.84%$-11.61 M-2317.9%68.51%
2015$0.27 M-45.97%$-1.66 M-611.6%-85.75%

Quarterly financial results

Reported quarter income marked $-4.61 M with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Acasti Pharma sales marked a tight movement and remained constant a nan%. Looking back to recent quarterly results, Acasti Pharma posted 6 negative quarters in a row.
ACST quarterly Sales and Income evolution

Acasti Pharma ownership

Reviewing Acasti Pharma ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Acasti Pharma, 9.29% of all outstanding shares are owned by its staff.

In case of Acasti Pharma stock, 6.09% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ACST stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Acasti Pharma:

Market cap$58.6 M
Total shares90.2 M
Float shares81.8 M
  - Institutional holdings (%)6.1%
  - Insider holdings (%)9.3%
Shares in short selling0.0%

ACST summary

Friday, May 22nd, 2020
Day range$0.61 - $0.65
Previous close$0.63
Session gain3.17%
Average true range$0.05
50d mov avg$0.49
100d mov avg$0.68
200d mov avg$1.35
Daily patternlt06a
Weekly pattern lt11a

Acasti Pharma performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We chose as the bechmarking frame for Acasti Pharma stock.
ACSTAcasti Pharma16.07%-68.14%-26.14%

Acasti Pharma competitors

Unfortunately, we could not find any public company that could be defined as Acasti Pharma competitor. This doesn't mean Acasti Pharma does not have any competitor in the market, it's just we could not detected it.